{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:37:56Z","timestamp":1788349076277,"version":"build-2803163510"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T00:00:00Z","timestamp":1719100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejphar.2024.176755","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T16:11:24Z","timestamp":1718986284000},"page":"176755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Neuromodulatory effects of leukotriene receptor antagonists: A comprehensive review"],"prefix":"10.1016","volume":"978","author":[{"given":"Radhika","family":"Sood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Anoopkumar-Dukie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Rudrawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-0466","authenticated-orcid":false,"given":"Susan","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.176755_bib1","series-title":"Neuroprotection by Montelukast against Rotenone-Induced Rat Brain Damage","author":"Abdel-Salam","year":"2018"},{"key":"10.1016\/j.ejphar.2024.176755_bib2","doi-asserted-by":"crossref","first-page":"P607","DOI":"10.1016\/j.jalz.2017.06.658","article-title":"Repurposing of the anti-asthmatic drug montelukast for the treamtment of Alzheimer's disease","volume":"13","author":"Aigner","year":"2017","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2024.176755_bib3","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1080\/00207454.2020.1769618","article-title":"Montelukast, a cysteinyl leukotriene receptor antagonist, exerts local antinociception in animal model of pain through the L-arginine\/nitric oxide\/cyclic GMP\/KATP channel pathway and PPARgamma receptors","volume":"131","author":"Alizamani","year":"2021","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176755_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fncel.2020.00090","article-title":"Going the extra (synaptic) mile: excitotoxicity as the road toward neurodegenerative diseases","volume":"14","author":"Armada-Moreira","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176755_bib5","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2174\/1381612043453072","article-title":"Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases","volume":"10","author":"Asanuma","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejphar.2024.176755_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2024.176755_bib7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.phrs.2017.11.021","article-title":"Mild cognitive impairment due to Alzheimer disease: contemporary approaches to diagnostics and pharmacological intervention","volume":"129","author":"Bachurin","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2024.176755_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10557-008-6140-9","article-title":"Leukotriene signaling in atherosclerosis and ischemia","volume":"23","author":"B\u00e4ck","year":"2009","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejphar.2024.176755_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(96)00700-5","article-title":"The cysteinyl-leukotriene receptor antagonist BAY u9773 is a competitive antagonist of leukotriene C4 in the Guinea-pig ileum","volume":"317","author":"B\u00e4ck","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176755_bib10","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1111\/bph.12665","article-title":"Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7","volume":"171","author":"B\u00e4ck","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176755_bib11","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1523\/JNEUROSCI.21-17-06480.2001","article-title":"Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity","volume":"21","author":"Bal-Price","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176755_bib12","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.1073\/pnas.1605957113","article-title":"Leukotriene E4 elicits respiratory epithelial cell mucin release through the G-protein\u2013coupled receptor, GPR99","volume":"113","author":"Bankova","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2024.176755_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810161","article-title":"Elucidating the neuroprotective role of ppars in Parkinson's disease: a neoteric and prospective target","volume":"22","author":"Behl","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176755_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.tins.2008.06.005","article-title":"Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease","volume":"31","author":"Bezprozvanny","year":"2008","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2024.176755_bib15","first-page":"76","article-title":"The use of leukotriene receptor antagonists (LTRAs) as complementary therapy in asthma","volume":"57","author":"Bjermer","year":"2002","journal-title":"Monaldi Arch. Chest Dis."},{"key":"10.1016\/j.ejphar.2024.176755_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bmcl.2016.11.049","article-title":"Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache","volume":"27","author":"Blanco","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2024.176755_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pneurobio.2005.06.004","article-title":"Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism","volume":"76","author":"Block","year":"2005","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejphar.2024.176755_bib18","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1089\/adt.2015.29015.beddrrr","article-title":"Creating new economic incentives for repurposing generic drugs for unsolved diseases using social finance","volume":"13","author":"Bloom","year":"2015","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ejphar.2024.176755_bib19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0197-4580(96)00109-1","article-title":"Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal","volume":"17","author":"Breitner","year":"1996","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejphar.2024.176755_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2023.109517","article-title":"Distribution of the cysteinyl leukotriene system components in the human, rat and mouse eye","volume":"232","author":"Brunner","year":"2023","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejphar.2024.176755_bib21","series-title":"Gilman's the Pharmacological Basis of Therapeutics","author":"Brunton","year":"2018"},{"key":"10.1016\/j.ejphar.2024.176755_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.37506\/ijfmt.v15i2.14325","article-title":"Leukotrienes and inflammation\u2013A review","volume":"15","author":"Butola","year":"2021","journal-title":"Indian Journal of Forensic Medicine & Toxicology"},{"key":"10.1016\/j.ejphar.2024.176755_bib23","first-page":"306","article-title":"Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I","volume":"8","author":"Carley","year":"2005","journal-title":"Idrugs"},{"key":"10.1016\/j.ejphar.2024.176755_bib24","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/oby.2009.192","article-title":"12\/15\u2010lipoxygenase products induce inflammation and impair insulin signaling in 3T3\u2010L1 adipocytes","volume":"17","author":"Chakrabarti","year":"2009","journal-title":"Obesity"},{"key":"10.1016\/j.ejphar.2024.176755_bib25","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/j.1460-9568.2012.08165.x","article-title":"AMPA receptors as drug targets in neurological disease\u2013advantages, caveats, and future outlook","volume":"35","author":"Chang","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176755_bib26","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.bbi.2020.03.022","article-title":"5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer's disease","volume":"88","author":"Chen","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejphar.2024.176755_bib27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbalip.2012.07.015","article-title":"Lysophospholipids and their receptors in the central nervous system","volume":"1831","author":"Choi","year":"2013","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ejphar.2024.176755_bib28","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1038\/sj.emboj.7601341","article-title":"The orphan receptor GPR17 identified as a new dual uracil nucleotides\/cysteinyl-leukotrienes receptor","volume":"25","author":"Ciana","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2024.176755_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11882-015-0564-7","article-title":"Antileukotrienes in upper airway inflammatory diseases","volume":"15","author":"Cingi","year":"2015","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.ejphar.2024.176755_bib30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2024.176755_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.expneurol.2014.03.008","article-title":"Blocking leukotriene synthesis attenuates the pathophysiology of traumatic brain injury and associated cognitive deficits","volume":"256","author":"Corser-Jensen","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2024.176755_bib32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/pr.117.014753","article-title":"Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach","volume":"70","author":"Cuadrado","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2024.176755_bib33","first-page":"872","article-title":"Leukotriene-receptor antagonists. Role in asthma management","volume":"46","author":"D'Urzo","year":"2000","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.ejphar.2024.176755_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/ijms24010261","article-title":"Functional heterodimerization between the G protein-coupled receptor GPR17 and the chemokine receptors 2 and 4: new evidence","volume":"24","author":"Daniele","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176755_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100077","article-title":"AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate","volume":"9","author":"Delijewski","year":"2021","journal-title":"Medicine in Drug Discovery"},{"key":"10.1016\/j.ejphar.2024.176755_bib36","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/j.1745-7254.2006.00438.x","article-title":"Cysteinyl leukotriene receptor 1 is involved in N-methyl-D-aspartate-mediated neuronal injury in mice","volume":"27","author":"Ding","year":"2006","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2024.176755_bib37","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jnc.13607","article-title":"Neuroinflammation: the devil is in the details","volume":"139","author":"DiSabato","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2024.176755_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-021-01353-0","article-title":"Parenchymal neuroinflammatory signaling and dural neurogenic inflammation in migraine","volume":"22","author":"Erdener","year":"2021","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176755_bib39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.prostaglandins.2012.09.002","article-title":"Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury","volume":"99","author":"Er\u015fahin","year":"2012","journal-title":"Prostaglandins Other Lipid Mediators"},{"key":"10.1016\/j.ejphar.2024.176755_bib40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0090-6980(02)00057-6","article-title":"Cysteinyl leukotriene receptors","volume":"68\u201369","author":"Evans","year":"2002","journal-title":"Prostag. Other Lipid Mediat."},{"key":"10.1016\/j.ejphar.2024.176755_bib41","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.neuroscience.2006.02.051","article-title":"Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats","volume":"140","author":"Fang","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2024.176755_bib42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1471-4159.2006.04371.x","article-title":"Modulation of inflammation in brain: a matter of fat","volume":"101","author":"Farooqui","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2024.176755_bib43","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1096\/fasebj.1.3.3040505","article-title":"Leukotrienes in health and disease","volume":"1","author":"Feuerstein","year":"1987","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejphar.2024.176755_bib44","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00702-013-1144-4","article-title":"Dural neurogenic inflammation induced by neuropathic pain is specific to cranial region","volume":"121","author":"Filipovi\u0107","year":"2014","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.ejphar.2024.176755_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277307","article-title":"Cysteinyl leukotriene receptor 1 is dispensable for osteoclast differentiation and bone resorption","volume":"17","author":"Fujita","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2024.176755_bib46","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1073\/pnas.83.21.8333","article-title":"Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase","volume":"83","author":"Furman","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2024.176755_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/JAA.S121276","article-title":"Environmental triggers and avoidance in the management of asthma","volume":"10","author":"Gautier","year":"2017","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.ejphar.2024.176755_bib48","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3454212","article-title":"Cysteinyl leukotrienes as potential pharmacological targets for cerebral diseases","volume":"2017","author":"Gelosa","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejphar.2024.176755_bib49","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/cns.12596","article-title":"Cysteinyl leukotrienes and their receptors: emerging therapeutic targets in central nervous system disorders","volume":"22","author":"Ghosh","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejphar.2024.176755_bib50","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11096-020-01160-8","article-title":"A possible effect of montelukast on neurological aging examined by the use of register data","volume":"43","author":"Grinde","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.ejphar.2024.176755_bib51","doi-asserted-by":"crossref","first-page":"15291","DOI":"10.1074\/jbc.M113.458901","article-title":"Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors","volume":"288","author":"Gyoneva","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.176755_bib52","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1021\/cr200246d","article-title":"Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease","volume":"111","author":"Haeggstrom","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejphar.2024.176755_bib53","series-title":"SmithKline Beecham Pharmaceuticals' Cysteinyl Leukotriene Receptor Antagonists: Pranlukast (SB 205312; Ono-1078; Onon), Pobilukast (SK&F 104353) and SK&F 106203, Novel Inhibitors of Leukotrienes","first-page":"317","author":"Hay","year":"1999"},{"key":"10.1016\/j.ejphar.2024.176755_bib54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2024.176755_bib55","doi-asserted-by":"crossref","first-page":"30531","DOI":"10.1074\/jbc.M003490200","article-title":"Characterization of the human cysteinyl leukotriene 2 receptor","volume":"275","author":"Heise","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.176755_bib56","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2024.176755_bib57","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.neuropharm.2014.01.011","article-title":"Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates A\u03b21-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice","volume":"79","author":"Hu","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2024.176755_bib58","doi-asserted-by":"crossref","first-page":"16033","DOI":"10.1021\/acs.jmedchem.2c01070","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway in the treatment of human diseases: current status, trends, and solutions","volume":"65","author":"Huang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2024.176755_bib59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2012.06.001","article-title":"Role of leukotriene receptor antagonists in asthma","volume":"53","author":"Hung","year":"2012","journal-title":"Pediatrics & Neonatology"},{"key":"10.1016\/j.ejphar.2024.176755_bib60","first-page":"685","article-title":"Current quest in natural bioactive compounds for alzheimer's disease: multi-targeted-designed-ligand based approach with preclinical and clinical based evidence","volume":"22","author":"Iqubal","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejphar.2024.176755_bib61","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1021\/acs.jmedchem.5b00741","article-title":"Discovery of gemilukast (ONO-6950), a dual CysLT1 and CysLT2 antagonist as a therapeutic agent for asthma","volume":"58","author":"Itadani","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2024.176755_bib62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbi.2012.12.008","article-title":"The inflammasome: pathways linking psychological stress, depression, and systemic illnesses","volume":"31","author":"Iwata","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejphar.2024.176755_bib63","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/WNR.0000000000000740","article-title":"Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson's disease","volume":"28","author":"Jang","year":"2017","journal-title":"Neuroreport"},{"key":"10.1016\/j.ejphar.2024.176755_bib64","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1582-4934.2010.01010.x","article-title":"Basic mechanisms of neurodegeneration: a critical update","volume":"14","author":"Jellinger","year":"2010","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2024.176755_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20143580","article-title":"The role of leukotrienes as potential therapeutic targets in allergic disorders","volume":"20","author":"Jo-Watanabe","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176755_bib66","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.neuropharm.2013.06.014","article-title":"Protection of dopaminergic neurons by 5-lipoxygenase inhibitor","volume":"73","author":"Kang","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2024.176755_bib67","series-title":"Calcium, Membranes, Aging, and Alzheimers-Disease-Introduction and Overview","first-page":"1","author":"Khachaturian","year":"1989"},{"key":"10.1016\/j.ejphar.2024.176755_bib68","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s43440-021-00258-8","article-title":"Mechanistic insight on the role of leukotriene receptors in ischemic\u2013reperfusion injury","volume":"73","author":"Khan","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2024.176755_bib69","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1164\/ajrccm\/144.3_Pt_1.617","article-title":"MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human","volume":"144","author":"Kips","year":"1991","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ejphar.2024.176755_bib70","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/tra.12881","article-title":"Cysteinyl leukotriene receptor 1 is a potent regulator of the endosomal-lysosomal system in the ARPE-19 retinal pigment epithelial cell line","volume":"24","author":"Koller","year":"2023","journal-title":"Traffic"},{"key":"10.1016\/j.ejphar.2024.176755_bib71","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/00023210-200216090-00003","article-title":"New and emerging prophylactic agents for migraine","volume":"16","author":"Krymchantowski","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2024.176755_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.ejphar.2024.176755_bib73","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.neuropharm.2014.01.011","article-title":"Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Abeta1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice","volume":"79","author":"Lai","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2024.176755_bib74","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuint.2014.05.006","article-title":"Montelukast rescues primary neurons against Abeta1-42-induced toxicity through inhibiting CysLT1R-mediated NF-kappaB signaling","volume":"75","author":"Lai","year":"2014","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2024.176755_bib75","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1365-2222.2012.03982.x","article-title":"Cysteinyl leukotriene receptors, old and new; implications for asthma","volume":"42","author":"Laidlaw","year":"2012","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.ejphar.2024.176755_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031851","article-title":"A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics","volume":"23","author":"Lamptey","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176755_bib77","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0197-4580(87)90074-1","article-title":"\u2018Increased calcium-current\u2019hypothesis of brain aging","volume":"8","author":"Landfield","year":"1987","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejphar.2024.176755_bib78","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1126\/science.6494926","article-title":"Prolonged Ca2+-dependent afterhyperpolarizations in hippocampal neurons of aged rats","volume":"226","author":"Landfield","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2024.176755_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022363","article-title":"Differential inhibitory effects of CysLT1 receptor antagonists on P2Y6 receptor-mediated signaling and ion transport in human bronchial epithelia","volume":"6","author":"Lau","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2024.176755_bib80","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.neuroscience.2014.07.058","article-title":"Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction","volume":"277","author":"Lenz","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2024.176755_bib82","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s11239-020-02098-4","article-title":"The role of P2Y12 receptor inhibition in ischemic stroke on microglia, platelets and vascular smooth muscle cells","volume":"50","author":"Li","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ejphar.2024.176755_bib83","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2024.176755_bib84","article-title":"Cytokines: from clinical significance to quantification","volume":"8","author":"Liu","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejphar.2024.176755_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105922","article-title":"Deficiency of astrocyte CysLT1R ameliorates depression-like behaviors in mice by modulating glutamate synaptic transmission","volume":"175","author":"Liu","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2024.176755_bib86","doi-asserted-by":"crossref","first-page":"58","DOI":"10.31083\/j.jin2203058","article-title":"New insights into molecular mechanisms underlying neurodegenerative disorders","volume":"22","author":"Liu","year":"2023","journal-title":"J. Integr. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176755_bib87","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0079-2023","article-title":"Neuropsychiatric events associated with montelukast in patients with asthma: a systematic review","volume":"32","author":"Lo","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ejphar.2024.176755_bib88","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/21658","article-title":"Characterization of the human cysteinyl leukotriene CysLT1 receptor","volume":"399","author":"Lynch","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2024.176755_bib89","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-neuro-090919-022842","article-title":"Synaptic plasticity forms and functions","volume":"43","author":"Magee","year":"2020","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176755_bib90","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/cas.12340","article-title":"5-Lipoxygenase and cysteinyl leukotriene receptor 1 regulate epidermal growth factor-induced cell migration through Tiam1 upregulation and Rac1 activation","volume":"105","author":"Magi","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejphar.2024.176755_bib91","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJM199012203232504","article-title":"Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4\u2013receptor antagonist","volume":"323","author":"Manning","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.176755_bib92","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.taap.2018.09.012","article-title":"Montelukast attenuates rotenone-induced microglial activation\/p38 MAPK expression in rats: possible role of its antioxidant, anti-inflammatory and antiapoptotic effects","volume":"358","author":"Mansour","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176755_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/ph15091039","article-title":"Leukotrienes vs. Montelukast-activity, metabolism, and toxicity hints for repurposing","volume":"15","author":"Marques","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2024.176755_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121056","article-title":"The mechanisms underlying montelukast's neuropsychiatric effects-new insights from a combined metabolic and multiomics approach","volume":"310","author":"Marques","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2024.176755_bib95","doi-asserted-by":"crossref","first-page":"8466","DOI":"10.1038\/ncomms9466","article-title":"Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug","volume":"6","author":"Marschallinger","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2024.176755_bib96","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s13311-020-00836-3","article-title":"The leukotriene receptor antagonist montelukast reduces alpha-synuclein load and restores memory in an animal model of dementia with lewy bodies","volume":"17","author":"Marschallinger","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2024.176755_bib97","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejphar.2012.10.032","article-title":"Excitotoxicity: bridge to various triggers in neurodegenerative disorders","volume":"698","author":"Mehta","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176755_bib98","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.3390\/ijms22052782","article-title":"The leukotriene receptor antagonist montelukast attenuates neuroinflammation and affects cognition in transgenic 5xFAD mice","volume":"22","author":"Michael","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176755_bib99","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fonc.2012.00200","article-title":"The Keap1\u2013Nrf2 system in cancers: stress response and anabolic metabolism","volume":"2","author":"Mitsuishi","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2024.176755_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.997619","article-title":"PGC-1\u03b1 activity and mitochondrial dysfunction in preterm infants","volume":"13","author":"Mohammadi","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2024.176755_bib101","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/B978-0-444-64123-6.00017-5","article-title":"Neuroinflammation","volume":"175","author":"Mukhara","year":"2020","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ejphar.2024.176755_bib102","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.stem.2013.04.006","article-title":"ROS production and NF-\u03baB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation","volume":"12","author":"Myant","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejphar.2024.176755_bib103","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neulet.2018.05.052","article-title":"Effect of montelukast in experimental model of Parkinson's disease","volume":"682","author":"Nagarajan","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2024.176755_bib104","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10096-017-3114-5","article-title":"Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections","volume":"37","author":"Ng","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejphar.2024.176755_bib105","doi-asserted-by":"crossref","DOI":"10.1177\/2398212819901082","article-title":"The role of the immune system in driving neuroinflammation","volume":"4","author":"N\u00ed Chasaide","year":"2020","journal-title":"Brain Neurosci Adv"},{"key":"10.1016\/j.ejphar.2024.176755_bib106","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbrc.2005.09.052","article-title":"Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods","volume":"337","author":"Nonaka","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2024.176755_bib107","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jaci.2006.08.009","article-title":"The role of leukotrienes in airway inflammation","volume":"118","author":"Ogawa","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejphar.2024.176755_bib108","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.bbagen.2011.02.005","article-title":"Leukotrienes and airway inflammation","volume":"1810","author":"Okunishi","year":"2011","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.ejphar.2024.176755_bib109","series-title":"Advances in Protein Chemistry and Structural Biology","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apcsb.2017.01.003","article-title":"Chapter one - oxidative stress: love and hate history in central nervous system","author":"Ortiz","year":"2017"},{"key":"10.1016\/j.ejphar.2024.176755_bib110","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.3390\/ijms24076321","article-title":"Glia-neurotrophic factor relationships: possible role in pathobiology of neuroinflammation-related brain disorders","volume":"24","author":"Palasz","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176755_bib111","doi-asserted-by":"crossref","first-page":"16477","DOI":"10.1074\/jbc.M705822200","article-title":"Leukotriene E4 activates peroxisome proliferator-activated receptor \u03b3 and induces prostaglandin D2 generation by human mast cells","volume":"283","author":"Paruchuri","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.176755_bib112","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1084\/jem.20091240","article-title":"Leukotriene E4\u2013induced pulmonary inflammation is mediated by the P2Y12 receptor","volume":"206","author":"Paruchuri","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2024.176755_bib113","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1081-1206(10)61317-8","article-title":"The role of leukotrienes in allergic rhinitis","volume":"94","author":"Peters-Golden","year":"2005","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ejphar.2024.176755_bib114","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainresrev.2006.02.002","article-title":"Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders","volume":"52","author":"Phillis","year":"2006","journal-title":"Brain Res. Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176755_bib115","article-title":"ROS and brain diseases: the good, the bad, and the ugly","volume":"2013","author":"Popa-Wagner","year":"2013","journal-title":"Oxid. Med. Cell."},{"key":"10.1016\/j.ejphar.2024.176755_bib116","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI200317522","article-title":"Neurodegeneration: what is it and where are we?","volume":"111","author":"Przedborski","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2024.176755_bib117","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2024.176755_bib118","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejphar.2018.10.040","article-title":"A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer's disease","volume":"842","author":"Rahman","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176755_bib119","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/mi.6.4.6","article-title":"COX-2 in inflammation and resolution","volume":"6","author":"Rajakariar","year":"2006","journal-title":"Mol. Interv."},{"key":"10.1016\/j.ejphar.2024.176755_bib120","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.aag2590","article-title":"How neuroinflammation contributes to neurodegeneration","volume":"353","author":"Ransohoff","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2024.176755_bib121","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.plefa.2011.04.003","article-title":"Modulation of leukotriene D4 attenuates the development of seizures in mice","volume":"85","author":"Rehni","year":"2011","journal-title":"Prostagl. Leukot. Essent. Fat. Acids"},{"key":"10.1016\/j.ejphar.2024.176755_bib122","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2024.176755_bib123","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1042\/BST20110665","article-title":"Targeting phosphoinositide 3-kinase \u03b4 for allergic asthma","volume":"40","author":"Rowan","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejphar.2024.176755_bib124","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11064-014-1478-9","article-title":"Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats","volume":"40","author":"Saad","year":"2015","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejphar.2024.176755_bib125","first-page":"20","article-title":"Pathogenesis of neurodegenerative diseases and the protective role of natural bioactive components","volume":"43","author":"Samanta","year":"2024","journal-title":"J. Am. Nutraceutical Assoc."},{"key":"10.1016\/j.ejphar.2024.176755_bib126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147215","article-title":"When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis","volume":"11","author":"Scannell","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2024.176755_bib127","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1080\/00207454.2016.1212854","article-title":"Neuroinflammation pathways: a general review","volume":"127","author":"Shabab","year":"2017","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176755_bib128","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1124\/mol.116.107904","article-title":"The orphan receptor GPR17 is unresponsive to uracil nucleotides and cysteinyl leukotrienes","volume":"91","author":"Simon","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176755_bib129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/abbi.1995.1354","volume":"320","author":"Singh","year":"1995","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejphar.2024.176755_bib130","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000312669","article-title":"Cysteinyl leukotrienes and their receptors: molecular and functional characteristics","volume":"85","author":"Singh","year":"2010","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejphar.2024.176755_bib131","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fncel.2018.00072","article-title":"An inflammation-centric view of neurological disease: beyond the neuron","volume":"12","author":"Skaper","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176755_bib132","first-page":"22","article-title":"The role of LTRAs in the management of persistent asthma","volume":"108","author":"Stoloff","year":"2000","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ejphar.2024.176755_bib133","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/cei.13355","article-title":"Neuroimmune interactions: how the nervous and immune systems influence each other","volume":"197","author":"Taams","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejphar.2024.176755_bib134","first-page":"S131","article-title":"Exploring the neuroprotective effects of montelukast treatment in a rat model of quinolinic acid-induced neurotoxicity","volume":"48","author":"Tassan Mazzocco","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejphar.2024.176755_bib135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/JEP.S277720","article-title":"Montelukast: the new therapeutic option for the treatment of epilepsy","volume":"13","author":"Tesfaye","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176755_bib136","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1074\/jbc.M608197200","article-title":"Signaling by the cysteinyl-leukotriene receptor 2: involvement in chemokine gene transcription","volume":"283","author":"Thompson","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.176755_bib137","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0014-2999(94)00485-4","article-title":"BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes","volume":"264","author":"Tudhope","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176755_bib138","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.4049\/jimmunol.1100333","article-title":"Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and pathogenesis of experimental autoimmune encephalomyelitis","volume":"187","author":"Wang","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2024.176755_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2019.12.013","article-title":"Modulation of neuroinflammation by cysteinyl leukotriene 1 and 2 receptors: implications for cerebral ischemia and neurodegenerative diseases","volume":"87","author":"Wang","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejphar.2024.176755_bib140","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.amjmed.2003.10.030","article-title":"Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis","volume":"116","author":"Wilson","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejphar.2024.176755_bib141","doi-asserted-by":"crossref","first-page":"610","DOI":"10.4103\/1673-5374.155436","article-title":"Neuroprotective effect of interleukin-6 regulation of voltage-gated Na(+) channels of cortical neurons is time- and dose-dependent","volume":"10","author":"Xia","year":"2015","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.ejphar.2024.176755_bib142","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12974-020-02029-3","article-title":"Neurotransmitter and neuropeptide regulation of mast cell function: a systematic review","volume":"17","author":"Xu","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejphar.2024.176755_bib143","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ejphar.2015.08.041","article-title":"Effects of ONO-6950, a novel dual cysteinyl leukotriene 1 and 2 receptors antagonist, in a Guinea pig model of asthma","volume":"765","author":"Yonetomi","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176755_bib144","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000081072","article-title":"Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice","volume":"73","author":"Yu","year":"2005","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejphar.2024.176755_bib145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/aps.2013.130","article-title":"Cysteinyl leukotriene receptor 1 mediates LTD4-induced activation of mouse microglial cells in vitro","volume":"35","author":"Yu","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2024.176755_bib146","first-page":"871","article-title":"Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats","volume":"23","author":"Zhang","year":"2002","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2024.176755_bib147","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neulet.2004.03.088","article-title":"Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors","volume":"363","author":"Zhang","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2024.176755_bib148","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1745-7254.2006.00458.x","article-title":"Cysteinyl leukotriene receptors CysLT1 and CysLT2 are upregulated in acute neuronal injury after focal cerebral ischemia in mice","volume":"27","author":"Zhang","year":"2006","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2024.176755_bib149","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neuro.2016.09.022","article-title":"Montelukast ameliorates streptozotocin-induced cognitive impairment and neurotoxicity in mice","volume":"57","author":"Zhang","year":"2016","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ejphar.2024.176755_bib150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2024.176755_bib151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2011.05.066","article-title":"Cysteinyl leukotriene receptor 2 is spatiotemporally involved in neuron injury, astrocytosis and microgliosis after focal cerebral ischemia in rats","volume":"189","author":"Zhao","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2024.176755_bib152","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.2042-7158.2010.01238.x","article-title":"Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats","volume":"63","author":"Zhao","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176755_bib153","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3389\/fphar.2020.00480","article-title":"Editorial: neuroinflammation and its resolution: from molecular mechanisms to therapeutic perspectives","volume":"11","author":"Zusso","year":"2020","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924004436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924004436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T20:11:43Z","timestamp":1721679103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924004436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":152,"alternative-id":["S0014299924004436"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176755","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromodulatory effects of leukotriene receptor antagonists: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"176755"}}